Host: Hussein Tawbi, MD, PhD <br>


  
    <p>This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.</p>

Host: Hussein Tawbi, MD, PhD This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.

Share Future Directions: Targeting LAG-3 in Melanoma Treatment

Sign up to save your podcasts

Future Directions: Targeting LAG-3 in Melanoma Treatment

Future Directions: Targeting LAG-3 in Melanoma Treatment